Aug 2026· Genetics and Molecular Research· 0 citations· 4 references
TL;DR
The study suggests the potential of CH-NLCs for improved oral delivery by formulating chitosan-coated AZM NLCs and optimizing using QbD approach.
Abstract
Objective: Azilsartan medoxomil (AZM) is a Class II antihypertensive drug with poor aqueous solubility that limit its dissolution and oral performance. The aim of present investigation was to improve its dissolution properties by formulating chitosan-coated AZM NLCs (CH-NLCs) and optimizing using QbD approach. Methods: Oleic acid, Compritol® 888 ATO, Kolliphor® RH 40, Chitosan as a liquid lipid, solid lipid, coating polymer and surfactant respectively. Chitosan coated AZM- NLCs were prepared by hot homogenization-ultrasonication method and optimized using BBD. Particle size, entrapment efficiency, zeta potential, DSC, FTIR, SEM and X-RD and release studies were evaluated. Results: Optimized CH-NLCs displayed particle size (172.25 ± 5.09 nm), entrapment efficiency (85.04 ± 2.61%), and zeta potential (+36.2 ± 1.2 mV). Solid-state analysis indicated reduced crystallinity and amorphous dispersion of AZM within the lipid–polymer matrix. The in vitro drug release (~92% over 24 h) showed diffusion-controlled release kinetics. Conclusion: The results of chitosan coated NLCs showed better drug loading and controlled release behaviour. The study suggests the potential of CH-NLCs for improved oral delivery.
This study showed that mucoadhesive polymeric nanoparticles of vonoprazan significantly enhanced solubility, pH-dependent release, and improved mucoadhesion, making it a promising approach to improve the oral bioavailability of drugs with poor water solubility.
S. Sajjad, U. Tulain, M. Asim et al.· International Journal of Nan...· 0 citations
The developed chitosan-coated Eudragit® S100 nanoparticle system represents a promising platform for sustained, colon-targeted oral delivery of HSP and other poorly bioavailable bioactive compounds.
The study was designed to formulate Repaglinide-loaded Nanostructured Lipid Carriers (NLCs) and assess their ability to improve the drug's solubility and dissolution characteristics, with the ultimate aim of enhancing its oral delivery potential. Five formulations of Repaglinide-loaded NLCs (F1-F5) were developed by em...
Radhika Kumari, Swatantra Kumar Singh, Diptee Gupta· GLOBAL JOURNAL OF PHARMACEUT...· 0 citations
Objective: To formulate and comprehensively characterize Repaglinide-loaded nanostructured lipid carriers (REP-NLCs) as a strategy to enhance its aqueous solubility, physicochemical stability, and oral bioavailability, thereby improving its therapeutic efficacy.
Methods: Repaglinide (REP) solubility was screened in var...
Mohamed A. Nasr-Eldin, Ibrahim A. Elbahwy, Suzan A. Abdelrazek et al.· International Journal of App...· 0 citations
The findings establish the PLGA–HPCD nanocomplex as a promising oral drug-delivery platform for enhancing the dissolution and therapeutic efficacy of diosmin.
Anh-Khoa Ton, Truc Thi-Anh Phan, M. Tran et al.· RSC Advances· 0 citations
Oxiconazole nitrate-loaded nanospheres were successfully developed using the emulsification–solvent evaporation method to enhance the solubility and dissolution of oxiconazole nitrate, a Biopharmaceutics Classification System (BCS) Class II antifungal drug characterized by low aqueous solubility and good membrane perme...
Suyash Shashikant Ingle, A. Chavan, Vasundhara Somnath Patil et al.· International Journal of Sci...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.